The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Officials from the FDA have approved flortaucipir F18 (Tauvid, Eli Lilly) for intravenous injection as the first drug used to help image a distinctive characteristic of Alzheimer disease in the brain called tau pathology.
Despite triptan availability as a migraine-specific rescue, the global burden of migraine morbidity remains high.
The FDA approval of solifenacin succinate marks the first for the treatment of young pediatric patients with NDO.
Officials with the FDA have approved apomorphine hydrochloride sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.
According to the study authors, patients with MS who underwent the 4-week mindfulness training not only showed greater improvement in processing speed and regulating negative emotions than those who did not participate in any training, but they also improved compared with those who tried adaptive cognitive training (ACT).
These accessible health care professionals are in a pivotal position to guide those who suffer from this neurological disorder to self-treatment or refer more serious cases to physicians.
This new study showed for the first time that an enzyme, known as fatty acid synthase (FASN), specifically may be responsible for causing cognitive deficits.
Individuals with the progressive condition often struggle to control their motor fluctuations.
Purdue University researchers have created technology that uses optical imaging to better help surgeons map out tumors in the body and understand how certain diseases affect activity in the brain.
The study involved measuring the levels and analyzing the expression patterns of more than 3000 proteins in a large number of brain and cerebrospinal fluid samples collected at multiple research centers across the United States.
The kinase inhibitor selumetinib was approved for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
Eptinezumab-jjmr, the first and only intravenous treatment for migraine prevention, is now commercially available in the United States.